It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
STUDY QUESTION
Can genome-wide genotyping data be analysed using a hypothesis-driven approach to enhance the understanding of the genetic basis of severe spermatogenic failure (SPGF) in male infertility?
SUMMARY ANSWER
Our findings revealed a significant association between SPGF and the SHOC1 gene and identified three novel genes (PCSK4, AP3B1, and DLK1) along with 32 potentially pathogenic rare variants in 30 genes that contribute to this condition.
WHAT IS KNOWN ALREADY
SPGF is a major cause of male infertility, often with an unknown aetiology. SPGF can be due to either multifactorial causes, including both common genetic variants in multiple genes and environmental factors, or highly damaging rare variants. Next-generation sequencing methods are useful for identifying rare mutations that explain monogenic forms of SPGF. Genome-wide association studies (GWASs) have become essential approaches for deciphering the intricate genetic landscape of complex diseases, offering a cost-effective and rapid means to genotype millions of genetic variants. Novel methods have demonstrated that GWAS datasets can be used to infer rare coding variants that are causal for male infertility phenotypes. However, this approach has not been previously applied to characterize the genetic component of a whole case–control cohort.
STUDY DESIGN, SIZE, DURATION
We employed a hypothesis-driven approach focusing on all genetic variation identified, using a GWAS platform and subsequent genotype imputation, encompassing over 20 million polymorphisms and a total of 1571 SPGF patients and 2431 controls. Both common (minor allele frequency, MAF > 0.01) and rare (MAF < 0.01) variants were investigated within a total of 1797 loci with a reported role in spermatogenesis. This gene panel was meticulously assembled through comprehensive searches in the literature and various databases focused on male infertility genetics.
PARTICIPANTS/MATERIALS, SETTING, METHODS
This study involved a European cohort using previously and newly generated data. Our analysis consisted of three independent methods: (i) variant-wise association analyses using logistic regression models, (ii) gene-wise association analyses using combined multivariate and collapsing burden tests, and (iii) identification and characterisation of highly damaging rare coding variants showing homozygosity only in SPGF patients.
MAIN RESULTS AND THE ROLE OF CHANCE
The variant-wise analyses revealed an association between SPGF and SHOC1-rs12347237 (P = 4.15E−06, odds ratio = 2.66), which was likely explained by an altered binding affinity of key transcription factors in regulatory regions and the disruptive effect of coding variants within the gene. Three additional genes (PCSK4, AP3B1, and DLK1) were identified as novel relevant players in human male infertility using the gene-wise burden test approach (P < 5.56E−04). Furthermore, we linked a total of 32 potentially pathogenic and recessive coding variants of the selected genes to 35 different cases.
LARGE SCALE DATA
Publicly available via GWAS catalog (accession number: GCST90239721).
LIMITATIONS, REASONS FOR CAUTION
The analysis of low-frequency variants presents challenges in achieving sufficient statistical power to detect genetic associations. Consequently, independent studies with larger sample sizes are essential to replicate our results. Additionally, the specific roles of the identified variants in the pathogenic mechanisms of SPGF should be assessed through functional experiments.
WIDER IMPLICATIONS OF THE FINDINGS
Our findings highlight the benefit of using GWAS genotyping to screen for both common and rare variants potentially implicated in idiopathic cases of SPGF, whether due to complex or monogenic causes. The discovery of novel genetic risk factors for SPGF and the elucidation of the underlying genetic causes provide new perspectives for personalized medicine and reproductive counselling.
STUDY FUNDING/COMPETING INTEREST(S)
This work was supported by the Spanish Ministry of Science and Innovation through the Spanish National Plan for Scientific and Technical Research and Innovation (PID2020-120157RB-I00) and the Andalusian Government through the research projects of ‘Plan Andaluz de Investigación, Desarrollo e Innovación (PAIDI 2020)’ (ref. PY20_00212) and ‘Proyectos de Investigación aplicada FEDER-UGR 2023’ (ref. C-CTS-273-UGR23). S.G.-M. was funded by the previously mentioned projects (ref. PY20_00212 and PID2020-120157RB-I00). A.G.-J. was funded by MCIN/AEI/10.13039/501100011033 and FSE ‘El FSE invierte en tu futuro’ (grant ref. FPU20/02926). IPATIMUP integrates the i3S Research Unit, which is partially supported by the Portuguese Foundation for Science and Technology (FCT), financed by the European Social Funds (COMPETE-FEDER) and National Funds (projects PEstC/SAU/LA0003/2013 and POCI-01-0145-FEDER-007274). S.S. is supported by FCT funds (10.54499/DL57/2016/CP1363/CT0019), ToxOmics-Centre for Toxicogenomics and Human Health, Genetics, Oncology and Human Toxicology, and is also partially supported by the Portuguese Foundation for Science and Technology (UIDP/00009/2020 and UIDB/00009/2020). S. Larriba received support from Instituto de Salud Carlos III (grant: DTS18/00101), co-funded by FEDER funds/European Regional Development Fund (ERDF)—a way to build Europe) and from ‘Generalitat de Catalunya’ (grant 2021SGR052). S. Larriba is also sponsored by the ‘Researchers Consolidation Program’ from the SNS-Dpt. Salut Generalitat de Catalunya (Exp. CES09/020). All authors declare no conflict of interest related to this study.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Departamento de Genética e Instituto de Biotecnología, Centro de Investigación Biomédica (CIBM), Universidad de Granada , Granada, Spain
2 Institute of Parasitology and Biomedicine López-Neyra (IPBLN), CSIC , Granada, Spain
3 IVIRMA Global Research Alliance, IVI Foundation, Instituto de Investigación Sanitaria La Fe (IIS La Fe) , Valencia, Spain
4 Instituto de Investigación Biosanitaria ibs. GRANADA , Granada, Spain
5 Servicio de Urología, Hospital Universitari i Politecnic La Fe e Instituto de Investigación Sanitaria La Fe (IIS La Fe) , Valencia, Spain
6 IVI-RMA Lisbon , Lisbon, Portugal
7 Ovoclinic & Ovobank, Clínicas de Reproducción Asistida y Banco de óvulos , Marbella, Málaga, Spain
8 Hospital Universitario Torrecárdenas, Unidad de Reproducción Humana Asistida , Almería, Spain
9 UGC de Obstetricia y Ginecología, Complejo Hospitalario de Jaén , Jaén, Spain
10 VIDA RECOLETAS Seville , Seville, Spain
11 Hospital Universitario Príncipe de Asturias , Alcalá de Henares, Madrid, Spain
12 Unidad de Urología, Hospital Universitario de Canarias , Santa Cruz de Tenerife, Spain
13 Departamento de Genética Humana, Instituto Nacional de Saúde Dr Ricardo Jorge , Lisbon, Portugal
14 Division of Gynecology and Reproductive Medicine, Department of Gynecology, Fertility Center, Humanitas Research Hospital, IRCCS , Milan, Italy
15 Laboratory of Seminology and Embryology, Andrology Service-Fundació Puigvert , Barcelona, Spain
16 i3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto , Porto, Portugal
17 Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) , Porto, Portugal
18 Human Molecular Genetics Group, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat , Barcelona, Spain